TREVOSE, Pa., Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector ...

In addition, “the use of biosimilar insulin, which was first approved in 2015, increased from 2.6% in 2017 to 8.2% in 2020 of total insulin treatment visits,” while “the total number of ...

The researchers found that insulin glargine was the most frequently used insulin, accounting for approximately half of treatment visits (2020: 2.6 million of 4.9 million visits).

Mylan also makes the distinction that this isn’t the Semglee brand pen, but unbranded Insulin Glargine-yfgn pens. This covers batch No. BF21002895, expiration August 2023.

Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. It will be available as a ...

Mylan also makes the distinction that this isn’t the Semglee brand pen, but unbranded Insulin Glargine-yfgn pens. This covers batch No. BF21002895, expiration August 2023.

Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection pens due to the potential for missing labels, according to a press release from the ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be available via prefilled pens and vials ...

The new pen pen holds 900 units of Toujeo (insulin glargine 300 Units/mL), more than any other long-acting insulin pen in the US, and provides up to 160 units/mL of Toujeo in a single injection.

Patients were randomly assigned (1:1) to receive their insulin using pen devices or vials and syringes. The study was conducted in accordance with the Declaration of Helsinki. [16] ...

The suspect insulin glargine lot was manufactured by India’s Biocon and distributed by Mylan Specialty across the U.S. between April 4 and May 5.

Lannett previously said that subject dosing has been completed in the pivotal clinical trial of Lannett/HEC's biosimilar insulin glargine and no serious adverse events were reported. The company ...